Showing 1 - 5 results of 5 for search 'Kangsheng Gu', query time: 0.02s Refine Results
  1. 1
    Patients with advanced cancer were treated with immune checkpoint inhibitors and injected with COVID-19 vaccine to improve their prognosis without increasing pancreatic related adverse events

    Patients with advanced cancer were treated with immune checkpoint inhibitors and injected with COVID-19 vaccine to improve their prognosis without increasing pancreatic related adv... by Min Li, Lingling Liao, Wei Huang, Hui Feng, Wanqing Wang, Nana Huang, Zhiyan Zhao, Yu Shi, Jinglu Ye, Kangsheng Gu

    Published 2024-12-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    Camrelizumab-based therapies for the treatment of advanced lung cancer: a prospective, open-label, multicenter, observational, real-world study

    Camrelizumab-based therapies for the treatment of advanced lung cancer: a prospective, open-label, multicenter, observational, real-world study by Dong Zhao, Minghong Bi, Xiaofei Cheng, Shuhong Wang, Huaidong Cheng, Xiaoyang Xia, Huan Chen, Yanbei Zhang, Zhiqiang Hu, Qisheng Cao, Hui Liang, Fan Wang, Xuhong Min, Ling Xu, Kehai Feng, Jinhua Zhou, Xinzhong Li, Rui Wang, Hua Xie, Xiaosi Chen, Kangsheng Gu

    Published 2025-03-01
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    First-line treatment of anti-EGFR monoclonal antibody cetuximab β plus FOLFIRI versus FOLFIRI alone in Chinese patients with RAS/BRAF wild-type metastatic colorectal cancer: a randomized, phase 3 trial

    First-line treatment of anti-EGFR monoclonal antibody cetuximab β plus FOLFIRI versus FOLFIRI alone in Chinese patients with RAS/BRAF wild-type metastatic colorectal cancer: a rand... by Yuankai Shi, Yi Ba, Junye Wang, Jianping Xiong, Kangsheng Gu, Yigui Chen, Zhendong Zheng, Zishu Wang, Weijian Guo, Ying Cheng, Xianli Yin, Yunpeng Liu, Yuxian Bai, Enxiao Li, Qi Li, Liangjun Zhu, Wei Li, Da Jiang, Jingdong He, Jiansi Chen, Jianguo Sun, Sheng Hou

    Published 2025-05-01
    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    Second-line pembrolizumab for advanced HCC: Meta-analysis of the phase III KEYNOTE-240 and KEYNOTE-394 studies

    Second-line pembrolizumab for advanced HCC: Meta-analysis of the phase III KEYNOTE-240 and KEYNOTE-394 studies by Richard S. Finn, Kangsheng Gu, Xi Chen, Philippe Merle, Kyung-Hun Lee, Mohamed Bouattour, Peiguo Cao, Wei Wang, Ann-Lii Cheng, Liangjun Zhu, Ho Yeong Lim, Masatoshi Kudo, Yueyin Pan, Ting-Tsung Chang, Julien Edeline, Wei Li, Ping Yang, Chen Li, Jianfeng Li, Abby B. Siegel, Shukui Qin

    Published 2025-06-01
    Get full text
    Article
    Save to List
    Saved in:
  5. 5
    Camrelizumab plus carboplatin and pemetrexed as first-line therapy for advanced non-squamous non-small-cell lung cancer: 5-year outcomes of the CameL randomized phase 3 study

    Camrelizumab plus carboplatin and pemetrexed as first-line therapy for advanced non-squamous non-small-cell lung cancer: 5-year outcomes of the CameL randomized phase 3 study by Jian Zhang, Ping Lu, Hui Zhao, Jianhua Chen, Wei Shi, Xiubao Ren, Yi Hu, Liping Wang, Hongmei Zhang, Chengchu Zhu, Jianping Xiong, Jianying Zhou, Jun Zhao, Yongqian Shu, Caicun Zhou, Xiaorong Dong, Yunpeng Liu, Yunchao Huang, Jian Zhao, Yiping Zhang, Sheng Hu, Xiaoyan Lin, Yueyin Pan, Jiuwei Cui, Lizhu Lin, Kangsheng Gu, Yun Fan, Qun Chen, Gongyan Chen, Zhehai Wang, Fengying Wu, Guangyu An, Shuliang Guo, Xiaodong Jiang, Yongsheng Wang, Jifeng Feng, Jianhua Shi, QiMing Wang, Jianan Huang, Lejie Cao, Jianhua Chang, Zhiyong He, Jian Fang, Faguang Jin, Hongjun Gao, Cuimin Ding, Xiangdong Zhou, Anwen Liu, Jianjin Huang, Beili Gao, Yinglan Chen, Chengping Hu, Zhigao Wang, Xinjing Ma

    Published 2024-11-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: